In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2732-2734

  Urban, Carl ^a,b   Mariano, Noriel ^a   Rahal, James J ^a,b  

^a NEW YORK HOSPITAL QUEENS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; POLYMYXIN B; RIFAMPICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG EFFICACY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RIFAMPIN;

EID: 77952607889     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01768-09     Document Type: Article

References (17)

1. Bradford, P. A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J. J. Rahal, S. Brooks, S. Cebular, and J. Quale. 2004. Emergence of carbapenem-resistant Klebsiella spp. possessing the class A carbapenemhydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
2. Bratu, S., P. Tolaney, U. Karumudi, J. Quale, M. Mooty, S. Nichani, and D. Landman. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Agents 56:128-132.
3. Chow, J. W., and V. L. Yu. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteremia: a commentary. Int. J. Antimicrob. Agents 11:7-12.
4. Deshpande, L. M., P. R. Rhomberg, H. S. Sader, and R. N. Jones. 2006. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005). Diagn. Microbiol. Infect. Dis. 56:367-372.
5. Elemam, A., J. Rahimian, and W. Mandell. 2009. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis. 49:271-274.
6. Huynh, H. K., D. J. Biedenbach, and R. N. Jones. 2006. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn. Microbiol. Infect. Dis. 55: 241-243.
7. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
8. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48:1313-1319.
9. Ostenson, R. C., B. T. Fields, and C. M. Nolan. 1977. Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob. Agents Chemother. 12:655-659.
10. Paterson, D. L., and Y. Doi. 2007. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin. Infect. Dis. 45:1179-1181.
11. Petrosillo, N., E. Ioannidou, and M. E. Falagas. 2008. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827.
12. Queenan, A. M., W. Shang, R. Flamm, and K. Bush. 2010. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem and meropenem. Antimicrob. Agents Chemother. 54:565-569.
13. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458.
14. Rahal, J. J. 2006. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 43(Suppl. 2):S95-S99.
15. Urban, C., and J. J. Rahal. 2004. Mechanisms of carbapenem resistance in Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Rev. Med. Microbiol. 15:63-72.
16. Urban, C., P. A. Bradford, M. Tuchman, S. Segal-Maurer, W. Wehbeh, L. Grenner, R. Colon-Urban, N. Mariano, and J. J. Rahal. 2008. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase β-lactamases associated with long-term care facilities. Clin. Infect. Dis. 46: e127-e130.
17. Yoon, J., C. Urban, C. Terzian, N. Mariano, and J. J. Rahal. 2004. In vitro double and triple synergistic activity of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-758.